128 related articles for article (PubMed ID: 11179836)
1. K-ras exon 2 point mutations in human endometrial cancer.
Semczuk A; Schneider-Stock R; Berbec H; Marzec B; Jakowicki JA; Roessner A
Cancer Lett; 2001 Mar; 164(2):207-12. PubMed ID: 11179836
[TBL] [Abstract][Full Text] [Related]
2. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
3. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
4. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations.
Semczuk A; Skomra D; Cybulski M; Jakowicki JA
Histochem J; 2001 Apr; 33(4):193-200. PubMed ID: 11550800
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium.
Manavi M; Bauer M; Baghestanian M; Berger A; Kucera E; Pischinger K; Battistutti W; Czerwenka K
Tumour Biol; 2001; 22(5):299-309. PubMed ID: 11553860
[TBL] [Abstract][Full Text] [Related]
8. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
9. K-ras point mutations in spontaneously occurring endometrial adenocarcinomas in the Donryu rat.
Tanoguchi K; Yaegashi N; Jiko K; Maekawa A; Sato S; Yajima A
Tohoku J Exp Med; 1999 Oct; 189(2):87-93. PubMed ID: 10775052
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy.
Wegman P; Ahlin C; Sorbe B
Int J Gynecol Cancer; 2011 Jan; 21(1):86-91. PubMed ID: 21330833
[TBL] [Abstract][Full Text] [Related]
11. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutations in endometrial carcinomas with microsatellite instability.
Lagarda H; Catasus L; Arguelles R; Matias-Guiu X; Prat J
J Pathol; 2001 Feb; 193(2):193-9. PubMed ID: 11180166
[TBL] [Abstract][Full Text] [Related]
13. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
14. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome.
Semczuk A; Berbeć H; Kostuch M; Cybulski M; Wojcierowski J; Baranowski W
J Cancer Res Clin Oncol; 1998; 124(12):695-700. PubMed ID: 9879831
[TBL] [Abstract][Full Text] [Related]
15. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient.
Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
Gynecol Oncol; 1996 Nov; 63(2):238-46. PubMed ID: 8910634
[TBL] [Abstract][Full Text] [Related]
16. Detection of K-ras mutations in cancerous lesions of human endometrium.
Semczuk A; Berbéc H; Kostuch M; Kotarski J; Wojcierowski J
Eur J Gynaecol Oncol; 1997; 18(1):80-3. PubMed ID: 9061333
[TBL] [Abstract][Full Text] [Related]
17. [Genetic alterations and transformations in development and establishment of uterine endometrial carcinomas].
Inoue M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Aug; 45(8):751-62. PubMed ID: 8371006
[TBL] [Abstract][Full Text] [Related]
18. P21 protein expression and ras-oncogene mutations in gastric carcinoma: correlation with clinical data.
Kasper HU; Schneider-Stock R; Mellin W; Roessner A
Int J Oncol; 1998 Jan; 12(1):69-74. PubMed ID: 9454888
[TBL] [Abstract][Full Text] [Related]
19. Incidence of p53 and ras gene mutations in DMBA-induced rat leukemias.
Wei S; Kito K; Miyoshi A; Matsumoto S; Kauzi A; Aramoto T; Abe Y; Ueda N
J Exp Clin Cancer Res; 2002 Sep; 21(3):389-96. PubMed ID: 12385583
[TBL] [Abstract][Full Text] [Related]
20. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
